{ }
The Global Fermented Beverages market, valued at 860 billion USD in 2024, is projected to reach 1.3 trillion USD by 2032, growing at a CAGR of 6.4%. The market analysis covers major regions including North America, Europe, and Asia-Pacific, with customization options available for specific countries and applications. Key players include Apple, Microsoft, and Nestlé, with insights into market dynamics, competitive landscape, and growth drivers such as lifestyle changes and technological advancements in fermentation.
Needham & Company has named Alcon (NYSE: ALC) its top pick for 2025, raising the price target to $108 and adding the stock to its Conviction List. The firm anticipates significant revenue growth from eight upcoming product launches, particularly the PanOptix Pro, which is expected to enhance earnings and margins.Analysts project robust performance in cataracts and contact lenses, with strong demand for intraocular lenses and a positive outlook for the Unity VCS launch. Valuation remains attractive, with a P/E ratio of 25.7x, indicating potential for multiple expansion as earnings outlook strengthens.
Needham & Company has named Alcon as its top pick for 2025, raising the price target to $108 and adding it to its Conviction List. The firm anticipates significant revenue growth from eight upcoming product launches, particularly the PanOptix Pro, which is expected to enhance margins and earnings by 2026. Analysts project robust performance in cataracts and contact lenses, with a favorable valuation at a P/E ratio of 25.7x, indicating a 14% discount to its historical average.
AbbVie is set to acquire Nimble Therapeutics for $200 million, enhancing its pipeline of oral peptide drugs targeting immune diseases like psoriasis and inflammatory bowel disease. Nimble's lead candidate aims to inhibit IL-23, similar to AbbVie’s Skyrizi, but offers an oral delivery method. This acquisition marks AbbVie’s third buyout of an immune drug developer this year, reflecting a strategic push to strengthen its immunology portfolio.
ICER's annual report criticizes major pharmaceutical companies, including Gilead, J&J, and Novartis, for "unsupported" price increases on ten drugs, leading to an additional $815 million in U.S. payer costs last year. Gilead's Biktarvy topped the list with a 5.9% hike, costing $359 million. Companies have pushed back, claiming ICER's methodology overlooks crucial clinical evidence and could hinder the development of new treatments.
The Medical Device Manufacturing Market is experiencing significant growth driven by technological advancements, particularly in AI, IoT, and virtual reality, which enhance product development and patient care. Companies face opportunities in emerging markets and evolving consumer preferences, but must navigate regulatory challenges and operational inefficiencies. Strategic partnerships and innovation are crucial for success in this dynamic landscape.
The Nanotechnology in Medicine and Healthcare Market report provides a comprehensive analysis of market trends, growth opportunities, and competitive dynamics from 2024 to 2031. It covers key segments, including nanoparticles and drug delivery applications, while offering insights into major players like Abbott Laboratories and Johnson & Johnson. The report also includes a SWOT analysis and highlights regional consumption patterns, aiding stakeholders in strategic decision-making.
The medical tapes market is projected to grow from USD 5.6 billion in 2024 to USD 7 billion by 2029, with a CAGR of 4.7%. Key growth drivers include rising healthcare expenditure, an aging population, and technological advancements in tape materials. North America leads the market, while the Asia-Pacific region shows rapid growth due to improving healthcare infrastructure.
Johnson & Johnson, a leader in the healthcare industry, faces challenges from shifting consumer preferences towards wellness, personalization, and e-commerce. While the company boasts a diversified product portfolio, strong brand reputation, and robust R&D capabilities, it must navigate regulatory pressures, litigation risks, and the need for effective public relations to maintain its market position. Additionally, J&J's commitment to corporate social responsibility and strategic partnerships enhances its growth potential in an evolving landscape.
Bristol Myers Squibb has filed a lawsuit against the federal government over a rejected plan to implement a 340B rebate model for drug discounts to hospitals, claiming the decision by HHS was unlawful. The company argues that its model would enhance compliance and transparency while addressing issues of abuse within the program. BMS intends to start this model with its Eliquis product in spring 2025, despite HHS's disapproval citing statutory inconsistencies.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.